These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 2597825)
21. Advantages of a low-osmolality ionic contrast medium in intra-arterial applications. Miller K Radiol Technol; 1987; 59(1):43-8. PubMed ID: 3659338 [TBL] [Abstract][Full Text] [Related]
22. Peripheral intravenous power injection of iodinated contrast media through 22G and 20G cannulas: can high flow rates be achieved safely? A clinical feasibility study. Schwab SA; Uder M; Anders K; Heinrich MC; Kuefner MA Rofo; 2009 Apr; 181(4):355-61. PubMed ID: 19280548 [TBL] [Abstract][Full Text] [Related]
23. [Prospective study of adverse reactions to contrast media administered intravenously--a comparison of low-osmolality and high-osmolality contrast media]. Higashi S; Takizawa K; Suzuki S; Nagashima J; Tamura S; Ishikawa M; Obuchi M; Katayama M Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Nov; 48(11):1364-70. PubMed ID: 3237463 [No Abstract] [Full Text] [Related]
24. [Side effects of using water-soluble iodine-containing contrast substances]. Perel'man VM Vestn Rentgenol Radiol; 1979; (5):81-4. PubMed ID: 506015 [No Abstract] [Full Text] [Related]
25. Noncompliance with guidelines for intravascular use of lower-osmolality contrast media. Damiani DR; Swanson DP; Hanwell LL Am J Hosp Pharm; 1993 Jun; 50(6):1204-6. PubMed ID: 8517462 [No Abstract] [Full Text] [Related]
26. Reducing the risk of ventricular fibrillation by adding sodium to ionic and non-ionic contrast media with low iodine concentration. Coronary perfusion of the isolated rabbit heart with meglumine diatrizoate or iopentol at 140 mg I/ml and 0-154 mmol Na+/l. Bååth L; Almén T Acta Radiol; 1989; 30(2):207-12. PubMed ID: 2647114 [TBL] [Abstract][Full Text] [Related]
27. [Complications related to the administration of iodinated contrast media]. Cappeliez O; Lemort M; Dagnelie J Rev Med Brux; 1997 Dec; 18(6):373-8. PubMed ID: 9481156 [TBL] [Abstract][Full Text] [Related]
28. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rudnick MR; Goldfarb S Rev Cardiovasc Med; 2003; 4 Suppl 5():S28-33. PubMed ID: 14668707 [TBL] [Abstract][Full Text] [Related]
29. The use of contrast media. Baerlocher MO; Asch M; Myers A CMAJ; 2010 Apr; 182(7):697. PubMed ID: 20231343 [No Abstract] [Full Text] [Related]
30. [Risk of hyperthyroidism in examinations with contrast media]. Hehrmann R; Klein D; Mayer D; Ploner O Aktuelle Radiol; 1996 Sep; 6(5):243-8. PubMed ID: 8991427 [TBL] [Abstract][Full Text] [Related]
31. [Renal tolerance during administration of iodinated contrast media in diabetic patients]. Deray G; Dubois M; Baumelou A; Jacobs C Diabete Metab; 1991; 17(3):379-82. PubMed ID: 1884883 [No Abstract] [Full Text] [Related]
38. Reactions to iodinated radiographic contrast agents. How to identify and manage patients at risk. Gluck BS; Mitty HA Postgrad Med; 1990 Oct; 88(5):187-9, 193-4. PubMed ID: 2216977 [TBL] [Abstract][Full Text] [Related]
39. Low-versus high-osmolality contrast media for intravenous use: a health care luxury or necessity? Powe NR Radiology; 1992 Apr; 183(1):21-2. PubMed ID: 1549674 [No Abstract] [Full Text] [Related]
40. [Comment on Circular No. 81 of the Ministry of Health concerning the side-effects of organo-iodated contrast media used in injections]. La Cavera A; Ariano R Minerva Med; 1976 Apr; 67(21):1365-7. PubMed ID: 934491 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]